Mulakan
ReutersReuters

Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism

RefinitivBacaan kurang dari 1 minit
RZLT

Rezolute Inc RZLT:

  • REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM

  • REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026

  • REZOLUTE INC - FDA CONFIRMS SUNRIZE TRIAL RESULTS EXPECTED IN DEC 2025 AS CLINCIAL EVIDENCE

ReutersSaham AS
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini

Lebih berita dari Reuters